Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer)
Single Arm Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT201) in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer)
Sponsor: Grit Biotechnology
Terminated
The study was terminated from a business perspective.
Other terminated trials from Grit Biotechnology
Other Adult trials with similar outcome
Listed as NCT06191900, this observational or N/A phase trial focuses on Adult and Gynecological Tumors and remains terminated or withdrawn. Sponsored by Grit Biotechnology, it has been updated 5 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
5 versions recorded-
Apr 28, 2026 — Present [daily]
Terminated
Status: Recruiting → Terminated · Phase: NA → None
-
Mar 2025 — Apr 2026 [monthly]
Recruiting NA
-
Sep 2024 — Mar 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Feb 2024 — Jul 2024 [monthly]
Recruiting NA
First recorded
Jun 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This study is an early exploration clinical study with one arm. The study consists of two stages, namely the dose escalation stage and the dose extension stage:
Contact Information
- Grit Biotechnology
For direct contact, visit the study record on ClinicalTrials.gov .